{"data":[{"accessionNo":"0002012383-26-003776","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS INC","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock","eventDate":"2026-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":5206581,"percentOfClass":7.1,"filedAt":"2026-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000315066-26-001988","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS INC","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":10713540.41,"percentOfClass":15,"filedAt":"2026-08-06","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000315066-26-001988","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS INC","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":10713540.41,"percentOfClass":15,"filedAt":"2026-08-06","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000947871-26-000651","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-22","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":"0001055951","personType":"IA","sharesOwned":6774507,"percentOfClass":9.5,"filedAt":"2026-06-24","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000947871-26-000651","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-22","reportingPerson":"ORBIMED CAPITAL GP VII LLC","reportingCik":"0001760648","personType":"OO","sharesOwned":6555102,"percentOfClass":9.2,"filedAt":"2026-06-24","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000947871-26-000651","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-22","reportingPerson":"ORBIMED GENESIS GP LLC","reportingCik":"0001808744","personType":"OO","sharesOwned":219405,"percentOfClass":0.3,"filedAt":"2026-06-24","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000947871-26-000651","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-22","reportingPerson":"ORBIMED CAPITAL LLC","reportingCik":"0001157524","personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-06-24","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001172661-26-002461","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Polar Capital Funds PLC - Biotechnology Fund","reportingCik":null,"personType":"OO","sharesOwned":5056807,"percentOfClass":8.46,"filedAt":"2026-06-22","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001172661-26-002461","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Polar Capital LLP","reportingCik":null,"personType":"IA","sharesOwned":5056807,"percentOfClass":8.46,"filedAt":"2026-06-22","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001172661-26-002461","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Polar Capital Holdings Plc","reportingCik":null,"personType":"HC","sharesOwned":5056807,"percentOfClass":8.46,"filedAt":"2026-06-22","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000947871-26-000636","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-15","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":"0001055951","personType":"IA","sharesOwned":7634630,"percentOfClass":10.93,"filedAt":"2026-06-17","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000947871-26-000636","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-15","reportingPerson":"ORBIMED CAPITAL GP VII LLC","reportingCik":"0001760648","personType":"OO","sharesOwned":7388902,"percentOfClass":10.58,"filedAt":"2026-06-17","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000947871-26-000636","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-15","reportingPerson":"ORBIMED GENESIS GP LLC","reportingCik":"0001808744","personType":"OO","sharesOwned":245728,"percentOfClass":0.35,"filedAt":"2026-06-17","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000947871-26-000636","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"COMMON STOCK","eventDate":"2026-06-15","reportingPerson":"ORBIMED CAPITAL LLC","reportingCik":"0001157524","personType":"IA","sharesOwned":31132,"percentOfClass":0.04,"filedAt":"2026-06-17","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001172661-26-002051","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Polar Capital LLP","reportingCik":null,"personType":"IA","sharesOwned":59800406,"percentOfClass":8.47,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001172661-26-002051","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Polar Capital Holdings Plc","reportingCik":null,"personType":"HC","sharesOwned":59800406,"percentOfClass":8.47,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001172661-26-002051","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Polar Capital Funds PLC - Biotechnology Fund","reportingCik":null,"personType":"OO","sharesOwned":59800406,"percentOfClass":8.47,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001172661-26-002402","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Polar Capital LLP","reportingCik":null,"personType":"IA","sharesOwned":5056807,"percentOfClass":8.46,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001172661-26-002402","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Polar Capital Holdings Plc","reportingCik":null,"personType":"HC","sharesOwned":5056807,"percentOfClass":8.46,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001172661-26-002402","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Polar Capital Funds PLC - Biotechnology Fund","reportingCik":null,"personType":"OO","sharesOwned":5056807,"percentOfClass":8.46,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001831942-26-000024","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4800940,"percentOfClass":7.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001831942-26-000024","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Michael Kramarz","reportingCik":null,"personType":"HC,IN","sharesOwned":4800940,"percentOfClass":7.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001831942-26-000024","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Robert Egen Atkinson","reportingCik":null,"personType":"HC,IN","sharesOwned":4800940,"percentOfClass":7.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001831942-26-000024","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":4800940,"percentOfClass":7.7,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000902664-26-002551","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Ryan Wilder","reportingCik":null,"personType":"HC,IN","sharesOwned":3250000,"percentOfClass":5.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000902664-26-002551","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Vestal Point Capital, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3250000,"percentOfClass":5.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001104659-26-062642","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Kiselak Tomas","reportingCik":null,"personType":"HC,IN","sharesOwned":1855644,"percentOfClass":3.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001104659-26-062642","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Peter Harwin","reportingCik":null,"personType":"HC,IN","sharesOwned":1855644,"percentOfClass":3.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001104659-26-062642","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Fairmount Healthcare Fund II L.P.","reportingCik":null,"personType":"PN","sharesOwned":1855644,"percentOfClass":3.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001104659-26-062642","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Fairmount Funds Management LLC","reportingCik":null,"personType":"IA","sharesOwned":1855644,"percentOfClass":3.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"VHCP Management III, LLC","reportingCik":null,"personType":"OO","sharesOwned":1726331,"percentOfClass":2.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Venrock Healthcare Capital Partners EG, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1726331,"percentOfClass":2.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"VHCP Management EG, LLC","reportingCik":null,"personType":"OO","sharesOwned":1726331,"percentOfClass":2.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Nimish Shah","reportingCik":null,"personType":"IN","sharesOwned":1726331,"percentOfClass":2.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Bong Y. Koh","reportingCik":null,"personType":"IN","sharesOwned":1726331,"percentOfClass":2.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Venrock Healthcare Capital Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1726331,"percentOfClass":2.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-26-000062","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":"29337E102","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"VHCP Co-Investment Holdings III, LLC","reportingCik":null,"personType":"OO","sharesOwned":1726331,"percentOfClass":2.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000902664-26-001079","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Vestal Point Capital, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3830000,"percentOfClass":6.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000902664-26-001079","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001672619","issuerName":"Enliven Therapeutics, Inc.","ticker":"ELVN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Ryan Wilder","reportingCik":null,"personType":"HC,IN","sharesOwned":3830000,"percentOfClass":6.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-25-000018","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Venrock Healthcare Capital Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3226331,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-25-000018","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"VHCP Co-Investment Holdings III, LLC","reportingCik":null,"personType":"OO","sharesOwned":3226331,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-25-000018","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Venrock Healthcare Capital Partners EG, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3226331,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-25-000018","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"VHCP Management III, LLC","reportingCik":null,"personType":"OO","sharesOwned":3226331,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-25-000018","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"VHCP Management EG, LLC","reportingCik":null,"personType":"OO","sharesOwned":3226331,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-25-000018","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Nimish Shah","reportingCik":null,"personType":"IN","sharesOwned":3226331,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0001738048-25-000018","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS, INC.","ticker":"ELVN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Bong Y. Koh","reportingCik":null,"personType":"IN","sharesOwned":3226331,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000315066-25-002752","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS INC","ticker":"ELVN","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":7870219,"percentOfClass":13.3,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"},{"accessionNo":"0000315066-25-002752","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001672619","issuerName":"ENLIVEN THERAPEUTICS INC","ticker":"ELVN","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":7870219,"percentOfClass":13.3,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/elvn"}],"updatedAt":"2026-11-03T18:39:25.530Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/elvn","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}